Source: Eur Respir J 2012; 40: 1277-1286
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
James A. Seddon, Peter Godfrey-Faussett, Kayleen Jacobs, Adam Ebrahim, Anneke C. Hesseling, H. Simon Schaaf. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J 2012; 40: 1277-1286

Member's Comments

No comment yet.

Related content which might interest you: Strategies against multidrug-resistant tuberculosis Source: Eur Respir J 2002; 20: 66S-77S Year: 2002 Treatment results and follow up of patients with chronic multidrug resistant tuberculosis Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005 Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh Source: Eur Respir J, 51 (3) 1701778; 10.1183/13993003.01778-2017 Year: 2018 Psychiatric issues during the treatment of the patients with multidrug-resistant tuberculosis Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005 Prevalence of inappropriate tuberculosis treatment regimens: a systematic review Source: Eur Respir J 2012; 39: 1012-1020 Year: 2012 Drug resistance pattern & response to supervised chemotherapy of drug resistant pulmonary tuberculosis - a study of hospitalized cases from tuberculosis diseases treatment centre Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003 Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis Source: Eur Respir J 2012; 39: 1511-1519 Year: 2012 Extensively drug resistant tuberculosis (XDR TB) in a high income country: a report of four unrelated cases Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009 The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis Source: Eur Respir J 2012; 39: 626-634 Year: 2012 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 Multi-drug resistant tuberculosis: a retrospective analysis of cases over 10 years in a low incidence setting Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones}, Source: Eur Respir J 2012; 40: 814-822 Year: 2012 Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998-2000 Source: Eur Respir J 2003; 21: 129-134 Year: 2003 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 Paradoxical reactions in non-HIV tuberculosis presenting as endobronchial obstruction Source: Eur Respir Rev 2009; 18: 295-299 Year: 2009 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 The WHO strategy for TB control and elimination Source: Eur Respir Mon 2012; 58: 242-253 Year: 2012 Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study Source: Eur Respir J 2006; 28: 980-985 Year: 2006